Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
October 26 2020 - 8:30AM
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will release financial results and business updates for the
third quarter of 2020 on Monday, November 2, 2020. The Company will
host a webcast and conference call that day at 8:30 a.m. Eastern
Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845
(domestic) or (765) 507-2618 (international) and referring to
conference ID number 9459728. A live webcast of the conference call
will be available online in the Investors and Media section of the
Company’s website at ir.minervaneurosciences.com. The archived
webcast will be available on the Company’s website beginning
approximately two hours after the event for 30 days.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone
(MIN-101), in clinical development for schizophrenia; a potential
royalty stream from seltorexant (MIN-202 or JNJ-42847922), in
clinical development for insomnia and major depressive disorder;
and MIN-301, in pre-clinical development for Parkinson’s disease.
Minerva’s common stock is listed on the NASDAQ Global Market under
the symbol “NERV.” For more information, please visit
www.minervaneurosciences.com.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024